Participants are being asked to
take part in this research study because they have either relapsed or refractory acute myeloid leukemia (AML).
Patients are asked to
take part in this research study because they have esophageal and gastroesophageal junction cancer treated with chemotherapy and radiotherapy followed by surgery (resected), but still have residual disease in resected tissue.
Participants have been asked to
take part in this research study because they have metastatic or surgically unresectable urothelial cancer with FGF / FGFR alterations.